Southern Biotechnology Associates, Inc., now known as SouthernBiotech, was founded in 1982, by scientists from Dr. Max Cooper’s Cellular Immunology Laboratory at the University of Alabama in Birmingham (UAB), as a company dedicated to the production, purification, conjugation and commercialization of the world’s highest quality, affinity purified, secondary antibodies for research use.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

XTALPI AND CK LIFE SCIENCES TO COLLABORATE IN AI-EMPOWERED TUMOUR VACCINE RESEARCH AND DEVELOPMENT, OPENING A NEW PARADIGM FOR SCIENTIFIC INNOVATION

XtalPi Inc. | November 25, 2022

news image

XtalPi announced today that they are embarking on a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group. XtalPi and CK Life Sciences will leverage their respective expertise to jointly develop a novel AI tumour vaccine R&D platform to improve the discovery and design capabilities of tumour vaccines and accelerate the development of more vaccine types. The goal of this collaboration is to realize precision treatment for patients worldwide. Accordin...

Read More

Medical

CARDEA BIO COMPLETES PLANNED LAUNCH OF CRISPR QC

Cardea Bio | April 06, 2022

news image

Today, Cardea Bio, Inc. - the world's only mass producer of biocompatible semiconductors - announced a significant milestone with the launch of CRISPR QC Inc. as a separate business using Cardea's CRISPR-chip™ technology for a range of quality control services for CRISPR gene editing. This milestone is an important move for Cardea Bio on its mission to realizing real-world applications of their BPU™ (Biosignal Processing Unit) Platform. After recently establish...

Read More

OPKO HEALTH ACQUIRES MODEX THERAPEUTICS, GAINS PROPRIETARY IMMUNOTHERAPY TECHNOLOGY WITH A FOCUS ON ONCOLOGY AND INFECTIOUS DISEASES

OPKO Health | May 10, 2022

news image

OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced the acquisition of ModeX Therapeutics, Inc. a privately held biotechnology company focused on developing innovative multi-specific immune therapies for cancer and infectious diseases. OPKO acquired ModeX for $300 million in OPKO common stock. Founded in October 2020 with headquarters in Natick, Mass., ModeX Therapeutics has developed highly flexible multi-specific antibody t...

Read More

Industry Outlook

FOXO TECHNOLOGIES LAUNCHES BIOINFORMATICS SERVICES TO REVOLUTIONIZE EPIGENETIC DATA ANALYSIS

Businesswire | July 20, 2023

news image

FOXO Technologies Inc.™ a leader in the field of commercializing epigenetic biomarker technology, announced the launch of its cutting-edge Bioinformatics Services to accelerate breakthroughs in biology, biotechnology, and healthcare, and redefine the growing field of epigenetic research. FOXO’s Bioinformatics Services offers a comprehensive platform of advanced data solutions tailored to meet the specific needs of clients in academia, healthcare, and pharmaceutical r...

Read More
news image

Industrial Impact

XTALPI AND CK LIFE SCIENCES TO COLLABORATE IN AI-EMPOWERED TUMOUR VACCINE RESEARCH AND DEVELOPMENT, OPENING A NEW PARADIGM FOR SCIENTIFIC INNOVATION

XtalPi Inc. | November 25, 2022

XtalPi announced today that they are embarking on a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group. XtalPi and CK Life Sciences will leverage their respective expertise to jointly develop a novel AI tumour vaccine R&D platform to improve the discovery and design capabilities of tumour vaccines and accelerate the development of more vaccine types. The goal of this collaboration is to realize precision treatment for patients worldwide. Accordin...

Read More
news image

Medical

CARDEA BIO COMPLETES PLANNED LAUNCH OF CRISPR QC

Cardea Bio | April 06, 2022

Today, Cardea Bio, Inc. - the world's only mass producer of biocompatible semiconductors - announced a significant milestone with the launch of CRISPR QC Inc. as a separate business using Cardea's CRISPR-chip™ technology for a range of quality control services for CRISPR gene editing. This milestone is an important move for Cardea Bio on its mission to realizing real-world applications of their BPU™ (Biosignal Processing Unit) Platform. After recently establish...

Read More
news image

OPKO HEALTH ACQUIRES MODEX THERAPEUTICS, GAINS PROPRIETARY IMMUNOTHERAPY TECHNOLOGY WITH A FOCUS ON ONCOLOGY AND INFECTIOUS DISEASES

OPKO Health | May 10, 2022

OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced the acquisition of ModeX Therapeutics, Inc. a privately held biotechnology company focused on developing innovative multi-specific immune therapies for cancer and infectious diseases. OPKO acquired ModeX for $300 million in OPKO common stock. Founded in October 2020 with headquarters in Natick, Mass., ModeX Therapeutics has developed highly flexible multi-specific antibody t...

Read More
news image

Industry Outlook

FOXO TECHNOLOGIES LAUNCHES BIOINFORMATICS SERVICES TO REVOLUTIONIZE EPIGENETIC DATA ANALYSIS

Businesswire | July 20, 2023

FOXO Technologies Inc.™ a leader in the field of commercializing epigenetic biomarker technology, announced the launch of its cutting-edge Bioinformatics Services to accelerate breakthroughs in biology, biotechnology, and healthcare, and redefine the growing field of epigenetic research. FOXO’s Bioinformatics Services offers a comprehensive platform of advanced data solutions tailored to meet the specific needs of clients in academia, healthcare, and pharmaceutical r...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us